You are here

BCRF Grantee Since


Donor Recognition

The Susan Hertog Award

Area(s) of Focus

Charles M. Perou, PhD

May Goldman Shaw Distinguished Professor of Molecular Oncology Research
Professor of Genetics & Pathology
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, North Carolina

Current Research

Dr. Perou’s work has shown that breast cancer is not a single disease, but instead, represents a series of diseases, that include the more favorable prognosis luminal A subtype and multiple worse prognosis subtypes including the luminal B, HER2-enriched, basal-like and Claudin-low types. Dr. Perou’s team is focused on identifying the causative genetic alterations that give rise to these poor prognosis subtypes through the use of genomic and proteomic technologies including mRNA-sequencing for gene expression patterns and genome sequencing to detect somatic mutations and DNA copy number changes. They are continuing to identify likely subtype-causative lesions in these aggressive tumor subtypes; for example the loss of TP53, RB1, and BRCA1 in basal-like tumors, which are also events that are commonly observed in serous ovarian cancers. The similarity between breast basal-like and ovarian cancers also extends to other aspects of the tumor genome, thus suggesting that these two tumor types might share an important common biology. In addition, Dr. Perou’s data suggests that cancer stem cells exist within some of these disease subtypes, especially basal-like and Claudin-low breast cancers, and this team is isolating these potential stem cells and functionally characterizing them. Lastly, these new genomic and genetic data are continuing to be used to build ever better statistical predictors of patient outcomes and response to therapy, including predictors of endocrine and chemotherapy benefit.

Mid-Year Summary

Dr. Perou has made significant progress in his studies of the causative genetic alterations that give rise to the poor prognosis breast cancer subtypes through the use of genomic and proteomic technologies. Between June 2013 and January 2014, he has had nine new publications, one paper in press, and four papers submitted and under review. BCRF funds continue to be the linchpin that serves to tie together many of his team’s different studies. They will continue many ongoing collaborations with other BCRF funded researchers including Drs. Lisa Carey, Hyman Muss, Shelton Earp, Matthew Ellis, Charlotte Kuperwasser, Geoff Wahl, Gordon Mills, Mitch Dowsett, Funmi Olopade, Carlos Arteaga, and the ALLIANCE and TBCRC, to name several of their most active collaborations.


Dr. Perou is a member of the Lineberger Comprehensive Cancer Center, the Carolina Center for Genome Sciences, and the Scientific Director of the UNC Genomics and Bioinformatics Core Facility. He received his Ph.D. in Cellular and Molecular Biology from the Department of Pathology at the University of Utah (1996) where he cloned and characterized the human Chediak-Higashi Syndrome gene. He next performed his postdoctoral training in the laboratory of David Botstein at Stanford University (1997-2000) where he began his genomic studies of human tumors using DNA microarrays. These genomic analyses resulted in the identification of novel subtypes of human breast tumors that predict patient survival times and response to therapy. Dr. Perou's laboratory at UNC is focused on using genomics, genetics, and animal models to decipher the underlying biology of the molecular subtypes of breast cancer, and then using this biological information to develop therapies that are specifically targeted against each of these distinct subtypes of breast cancer.

Latest from Charles M. Perou